Pharmaids Pharmaceuticals (524572) Q1 26/27 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved and published following a board meeting on August 12, 2026.

• The group operates in a single segment: Contract Research and Manufacturing Services.

Financial highlights

• Standalone revenue from operations for Q1 FY27 was Rs 111.53 lakhs, down from Rs 268.89 lakhs year-over-year and Rs 1,060.25 lakhs sequentially.

• Standalone net profit for Q1 FY27 was Rs 61.21 lakhs, compared to a loss of Rs 132.83 lakhs year-over-year.

• Consolidated revenue from operations for Q1 FY27 was Rs 412.14 lakhs, down from Rs 2,788.24 lakhs year-over-year.

• Consolidated net profit for Q1 FY27 was Rs 187.15 lakhs, compared to a loss of Rs 531.53 lakhs year-over-year.

• Basic and diluted EPS for Q1 FY27 were Rs 0.61 (standalone) and Rs 0.63 (consolidated), compared to negative EPS in the prior year.

Outlook and guidance

• The company will hold its 37th AGM via video conferencing, with further details to be shared.